Literature DB >> 11578325

Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer.

K. Bertelsen1, B. Hølund, E. Andersen.   

Abstract

From September 1981 to September 1986, 417 consecutive treated patients with epithelial ovarian cancer FIGO stage I and II were registered by the Danish Ovarian Cancer Group (DACOVA). Typing and grading were primarily performed by several pathologists, with and without training in gynecologic pathology. Review typing by one specially trained pathologist showed an agreement rate of 72% for serous and endometrioid carcinoma, 86% for mucinous and 100% for clear cell carcinoma. The agreement rate was calculated for patients primarily classified by pathologists trained in gynecologic pathology and for patients primarily classified by pathologists with and without training. The agreement rate was not better for the group of pathologists with special training in gynecologic pathology. Grading was performed according to two classifications: one based on architectural pattern and one on combined criteria. Review grading showed an agreement rate of 77% for architectural classification and an agreement rate of 52% for combined classification. The agreement rate between the two grade classifications at review was only 62%. Combined grading showed a significant tendency towards classifying more tumors as low grade. All grade classifications had prognostic value. The poor agreement rate of both type and grade even when performed by pathologists with expertise in gynecologic pathology, calls for a better and more reproducible characterization of malignant ovarian tumors.

Entities:  

Year:  1993        PMID: 11578325     DOI: 10.1046/j.1525-1438.1993.03020072.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Authors:  Charlotte Gerd Hannibal; Russell Vang; Jette Junge; Anette Kjaerbye-Thygesen; Robert J Kurman; Susanne K Kjaer
Journal:  Gynecol Oncol       Date:  2012-02-24       Impact factor: 5.482

2.  NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.

Authors:  Volker Endris; Albrecht Stenzinger; Nicole Pfarr; Roland Penzel; Markus Möbs; Dido Lenze; Silvia Darb-Esfahani; Michael Hummel; Andreas Jung; Ulrich Lehmann; Hans Kreipe; Thomas Kirchner; Reinhard Büttner; Wolfram Jochum; Gerald Höfler; Manfred Dietel; Wilko Weichert; Peter Schirmacher
Journal:  Virchows Arch       Date:  2016-03-22       Impact factor: 4.064

3.  Morphological and molecular basis of ovarian serous carcinoma.

Authors:  Daniel G Rosen; Zhihong Zhang; Weiwei Shan; Jinsong Liu
Journal:  J Biomed Res       Date:  2010-07

4.  Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery.

Authors:  H Kajiyama; K Shibata; M Mizuno; T Umezu; S Suzuki; A Nawa; M Kawai; T Nagasaka; F Kikkawa
Journal:  Br J Cancer       Date:  2011-10-04       Impact factor: 7.640

5.  The transcriptomic profile of ovarian cancer grading.

Authors:  Cindy Q Yao; Francis Nguyen; Syed Haider; Maud H W Starmans; Philippe Lambin; Paul C Boutros
Journal:  Cancer Med       Date:  2014-10-15       Impact factor: 4.452

6.  PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Authors:  Celestine S Tung; Samuel C Mok; Yvonne T M Tsang; Zhifei Zu; Huijuan Song; Jinsong Liu; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson; Kwong-Kwok Wong
Journal:  Mod Pathol       Date:  2009-06-12       Impact factor: 7.842

7.  Circular RNA MTO1 Inhibits the Proliferation and Invasion of Ovarian Cancer Cells Through the miR-182-5p/KLF15 Axis.

Authors:  Ning Wang; Qin-Xue Cao; Jun Tian; Lu Ren; Hai-Ling Cheng; Shao-Qin Yang
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.